NATCOPHARM vs ORCHPHARMA: Stock Comparison

Natco Pharma Limited vs Orchid Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Natco Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Orchid Pharma Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Natco Pharma Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NATCOPHARM is more favourable on 9 of 13 scored metrics and ORCHPHARMA on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,536 Cr vs ₹5,001 Cr
P/E Ratio
NATCOPHARM has a lower P/E
11.68x vs 244.44x
P/B Ratio
NATCOPHARM has a lower P/B
1.8x vs 3.9x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹4.01
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0%
Revenue Growth (TTM YoY)
ORCHPHARMA has faster revenue growth
-1.5% vs -39.6%
EPS Growth (TTM YoY)
ORCHPHARMA has faster EPS growth
0% vs -34.1%
Qtr Sales Growth
ORCHPHARMA has stronger quarterly sales growth
0.05% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNATCOPHARMORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNATCOPHARMORCHPHARMA
Live Price₹925.05₹985.35
Day Change-0.22%-0.26%
Volume1.52 L43,875
52-Week High₹1,226.8₹1,119.8
52-Week Low₹789₹480
Distance from 52W High-24.6%-12.01%

Valuation

MetricNATCOPHARMORCHPHARMA
Market Cap₹16,536 Cr₹5,001 Cr
P/E Ratio11.68x244.44x
P/B Ratio1.8x3.9x
EPS₹79.24₹4.01
Book Value₹514.92₹253.98
Dividend Yield0.52%0%

Growth

MetricNATCOPHARMORCHPHARMA
Revenue Growth (TTM YoY)-39.6%-1.5%
EPS Growth (TTM YoY)-34.1%0%
Qtr Sales Growth-39.5%0.05%
Qtr Profit Growth-34.1%4.26%

Profitability & Leverage

MetricNATCOPHARMORCHPHARMA
ROE16.9%2.12%
ROCE17.1%2.64%
Net Margin34.78%2.51%
Operating Margin35.2%5.07%
Debt to Equity0.08x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNATCOPHARMORCHPHARMA
Promoter Holding49.14%69.84%
FII Holding16.99% 0.38 pp0.81% 0.06 pp
DII Holding5.62% 0.16 pp20.75% 0.5 pp
Public Holding27.97% 0.22 pp8.61% 0.44 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Natco Pharma Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.